Incyte stock pre-market at EUR 107.65: plus 0.51 percent
Published on 10/01/2026 at 08:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Incyte stock was at EUR 107.65 in pre-market trading on Lang & Schwarz at 8:40 a.m. CEST on October 1, 2026. That was up EUR 0.55, or 0.51 percent, versus the Lang & Schwarz prior close of EUR 107.10 on September 30, 2026.
Incyte pre-market price
The Lang & Schwarz quote puts Incyte at EUR 107.65 before the Xetra open, compared with the prior close of EUR 107.10 on September 30, 2026. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Incyte stock.
FDA approval for Atebrioz
In a September 25, 2026 press release, Incyte and Mirum Pharmaceuticals said the U.S. Food and Drug Administration had approved Atebrioz, or zilurgisertib, to reduce the volume of total new heterotopic ossification in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva.
The release said Atebrioz was developed by Incyte and licensed to Mirum for worldwide development and commercialization. The recommended dose is 100 mg taken orally once daily, and the treatment was expected to become commercially available in the United States in October.
